Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Holding HUMA?
Track your performance easily
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.48 - $9.97
Previous CloseN/A
Volume1.64M
Average Volume (3M)6.37M
Market Cap
$602.17M
Enterprise Value$646.13M
Total Cash (Recent Filing)$225.50M
Total Debt (Recent Filing)$49.15M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 21, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding128,668,490
10 Day Avg. Volume5,398,402
30 Day Avg. Volume6,370,641
Standard Deviation0.30
R-Squared0.05
Alpha0.00055
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.55
Forecast
1Y Price Target
$11.60Price Target Upside147.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Humacyte News
PremiumCompany Announcements
Humacyte Receives FDA Approval for SYMVESS Launch
Bulls Say, Bears Say
Bulls Say
Market AdoptionThe company applied for a New Technology Add-on Payment with CMS, which could allow hospitals to receive reimbursement up to approximately 65% of Symvess’ cost, supporting its market adoption.
Product LaunchHUMA has recruited and trained a highly experienced sales force to support the SYMVESS launch, effectively addressing the US market opportunity.
Regulatory ApprovalThe FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury, which removes a major overhang on Humacyte stock.
Bears Say
Adverse EventsHigher adverse event rates observed for ATEV in the analysis, with thrombosis being the largest area of difference in adverse events.
Clinical TrialsRisks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and failure of products to show sufficient competitive differentiation.
Surgical Handling IssuesHandling issues by surgeons who are more familiar with stiff PTFE grafts compared to HUMA's softer device may have contributed to the thrombosis rate.
---
Ownership Overview
5.93% Insiders
5.64% Mutual Funds
<0.01% Other Institutional Investors
78.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $2.48 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $602.17M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Mar 21, 2025 which is in 70 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Nov 08, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.249 by -$0.081.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.25.
How many shares outstanding does Humacyte have?
Humacyte has 128,668,490 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.249. Following the earnings report the stock price went up 9.886%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
---
Humacyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.60 (147.86% Upside)
$11.60 (147.86% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 809.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
68.34%
12-Months-Change
Fundamentals
Return on Equity
239.90%
Trailing 12-Months
Asset Growth
-23.18%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. (HUMA) is a biotechnology company focused on developing and commercializing bioengineered human tissues and organs that are designed to treat a variety of diseases and conditions. The company primarily operates within the regenerative medicine sector, aiming to address critical needs in vascular and organ replacement. Humacyte's core product is its investigational Human Acellular Vessel (HAV), which is being explored for use in vascular surgeries and treatments for patients with end-stage renal disease, peripheral arterial disease, and other vascular conditions.
---
HUMA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$11.60
▲(147.86% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+3.49%
reiterated a buy rating 21 days ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.49% per trade.
---